Patent SG-11201809310P-A (SG)
Title: Isoquinolin-3-yl carboxamides and preparation and use thereof
Inventor: KC SUNIL KUMAR
IPC: C07D217/22
Filed: 2017-04-27
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 02 November 2017 (02.11.2017) WIP0 I PCT omit VIII VIII lII 0 HE Eloilloo 111E1111°111 (10) International Publication Number WO 2017/189823 A3 (51) International Patent Classification: CO7D 217/22 (2006.01) A61K 31/4725 (2006.01) A61K 31/472 (2006.01) CO7D 217/12 (2006.01) (21) International Application Number: PCT/US2017/029797 (22) International Filing Date: 27 April 2017 (27.04.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/328,210 27 April 2016 (27.04.2016) US (71) Applicant: SAMUMED, LLC [US/US]; 9381 Judicial Drive, Suite 160, San Diego, California 92121 (US). (72) Inventors: KC, Sunil Kumar; 10504 Clasico Court, San Diego, California 92127 (US). MITTAPALLI, Gopi Ku- mar; 4158 Decoro Street #47, San Diego, California 92122 (US). HOFILENA, Brian Joseph; 4049 Florida Street, #1, San Diego, California 92104 (US). MARAKOVITS, Joseph Timothy; 2403 Summerhill Drive, Encinitas, Cal- ifornia 92024 (US). CHIRUTA, Chandramouli; 4158 Decoro Street, Apt. 61, San Diego, California 92122 (US). MAK, Chi Ching; 12057 World Trade Drive, Unit 3, San Diego, Arizona 92128 (US). CAO, Jianguo; 9898 Avenger Court, San Diego, California 92126 (US). MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) (88) Date of publication of the international search report: 08 February 2018 (08.02.2018) W O 20 17 / 1898 23 A3 (74) Agent: DORIGO, Andrea et al.; Fish & Richardson P.C., PO Box 1022, Minneapolis, Minnesota 55440-1022 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, (54) Title: ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF (57) : Isoquinoline compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an isoquinoline compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, inflammation, auto-immune diseases and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as neurological conditions/disorders/diseases linked to overexpression of DYRK1A.